A detailed history of Vanguard Group Inc transactions in Agenus Inc stock. As of the latest transaction made, Vanguard Group Inc holds 34,401,122 shares of AGEN stock, worth $576 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
34,401,122
Previous 30,266,890 13.66%
Holding current value
$576 Million
Previous $25.1 Million 20.58%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$0.53 - $0.93 $2.19 Million - $3.84 Million
4,134,232 Added 13.66%
34,401,122 $20 Million
Q4 2023

Feb 14, 2024

BUY
$0.63 - $1.14 $2.1 Million - $3.79 Million
3,328,451 Added 12.36%
30,266,890 $25.1 Million
Q3 2023

Nov 14, 2023

BUY
$1.12 - $1.88 $484,066 - $812,539
432,202 Added 1.63%
26,938,439 $30.4 Million
Q2 2023

Aug 14, 2023

BUY
$1.31 - $2.04 $3.77 Million - $5.87 Million
2,878,357 Added 12.18%
26,506,237 $42.4 Million
Q1 2023

May 15, 2023

SELL
$1.45 - $2.95 $947,393 - $1.93 Million
-653,375 Reduced 2.69%
23,627,880 $35.9 Million
Q4 2022

Feb 10, 2023

BUY
$2.02 - $3.25 $2.89 Million - $4.65 Million
1,430,085 Added 6.26%
24,281,255 $58.3 Million
Q3 2022

Nov 14, 2022

BUY
$1.96 - $3.14 $3.28 Million - $5.26 Million
1,673,615 Added 7.9%
22,851,170 $46.8 Million
Q2 2022

Aug 12, 2022

BUY
$1.3 - $2.64 $3.61 Million - $7.33 Million
2,775,146 Added 15.08%
21,177,555 $41.1 Million
Q1 2022

May 13, 2022

BUY
$2.35 - $3.47 $1.8 Million - $2.66 Million
767,856 Added 4.35%
18,402,409 $45.3 Million
Q4 2021

Feb 14, 2022

BUY
$2.92 - $5.74 $7.88 Million - $15.5 Million
2,699,095 Added 18.07%
17,634,553 $56.8 Million
Q3 2021

Nov 12, 2021

BUY
$4.98 - $6.63 $5.14 Million - $6.84 Million
1,032,053 Added 7.42%
14,935,458 $78.4 Million
Q2 2021

Aug 13, 2021

BUY
$2.56 - $5.49 $35.6 Million - $76.3 Million
13,903,405 New
13,903,405 $76.3 Million

Others Institutions Holding AGEN

About AGENUS INC


  • Ticker AGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 283,163,008
  • Market Cap $4.74B
  • Description
  • Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs co...
More about AGEN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.